Risk of chemotherapy-induced febrile neutropenia with early discontinuation of pegfilgrastim prophylaxis in US clinical practice

PURPOSE: Accumulating evidence suggests that not all cancer chemotherapy patients who receive first-cycle pegfilgrastim prophylaxis continue to receive it in subsequent cycles and that these patients may be subsequently at higher risk of febrile neutropenia (FN). Additional evidence from US clinical...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Support Care Cancer
Egile Nagusiak: Weycker, Derek, Li, Xiaoyan, Barron, Rich, Li, Yanli, Reiner, Maureen, Kartashov, Alex, Figueredo, Jacqueline, Tzivelekis, Spiros, Garcia, Jacob
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Springer Berlin Heidelberg 2015
Gaiak:
Original Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC4846701/
https://ncbi.nlm.nih.gov/pubmed/26670915
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00520-015-3039-4
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak